Role of tau N-terminal motif in the secretion of human tau by End Binding proteins.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 28 05 2018
accepted: 03 01 2019
entrez: 23 1 2019
pubmed: 23 1 2019
medline: 23 10 2019
Statut: epublish

Résumé

For unknown reasons, humans appear to be particular susceptible to developing tau pathology leading to neurodegeneration. Transgenic mice are still undoubtedly the most popular and extensively used animal models for studying Alzheimer's disease and other tauopathies. While these murine models generally overexpress human tau in the mouse brain or specific brain regions, there are differences between endogenous mouse tau and human tau protein. Among them, a main difference between human and mouse tau is the presence of a short motif spanning residues 18 to 28 in the human tau protein that is missing in murine tau, and which could be at least partially responsible for that different susceptibility across species. Here we report novel data using affinity chromatography analysis indicating that the sequence containing human tau residues 18 to 28 acts a binding motif for End Binding proteins and that this interaction could facilitate tau secretion to the extracellular space.

Identifiants

pubmed: 30668577
doi: 10.1371/journal.pone.0210864
pii: PONE-D-18-15986
pmc: PMC6342323
doi:

Substances chimiques

MAPRE1 protein, human 0
MAPRE3 protein, human 0
MAPT protein, human 0
Mapt protein, mouse 0
Microtubule-Associated Proteins 0
Recombinant Proteins 0
tau Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0210864

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Proc Natl Acad Sci U S A. 2011 May 24;108(21):8826-31
pubmed: 21551097
Nat Cell Biol. 2009 Jul;11(7):909-13
pubmed: 19503072
Mol Cell Biochem. 1994 Jan 26;130(2):187-96
pubmed: 8028597
Nat Cell Biol. 2008 Oct;10(10):1181-9
pubmed: 18806788
FEBS Lett. 2006 Sep 4;580(20):4842-50
pubmed: 16914144
Biochemistry. 2001 May 22;40(20):5983-91
pubmed: 11352733
J Cell Biol. 2002 Nov 25;159(4):589-99
pubmed: 12446741
Mol Biol Cell. 2016 Oct 1;27(19):2924-34
pubmed: 27466319
Int J Dev Biol. 1994 Mar;38(1):13-25
pubmed: 8074993
J Neurosci. 2017 Nov 22;37(47):11406-11423
pubmed: 29054878
Cell Mol Life Sci. 2016 May;73(10):2053-77
pubmed: 26969328
Proc Natl Acad Sci U S A. 1988 Jun;85(11):4051-5
pubmed: 3131773
J Neurochem. 2015 Jun;133(5):653-67
pubmed: 25761518
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
J Neurochem. 1996 Oct;67(4):1622-32
pubmed: 8858947
Front Cell Neurosci. 2014 Apr 23;8:113
pubmed: 24795568
J Neurosci Res. 2013 Jul;91(7):954-62
pubmed: 23606524
PLoS One. 2012;7(2):e31302
pubmed: 22312444
Neuron. 2009 Jan 15;61(1):85-100
pubmed: 19146815
Mol Neurodegener. 2017 Aug 15;12(1):59
pubmed: 28810892
Cell Mol Neurobiol. 2006 Oct-Nov;26(7-8):1085-97
pubmed: 16779670
FEBS Lett. 2012 Jan 2;586(1):47-54
pubmed: 22138183
Science. 1988 Jan 15;239(4837):285-8
pubmed: 3122323
Acta Neuropathol Commun. 2017 Dec 19;5(1):99
pubmed: 29258615
Curr Biol. 2010 Jun 8;20(11):1023-8
pubmed: 20471267
Mol Cell Neurosci. 2008 Apr;37(4):673-81
pubmed: 18272392
J Biol Chem. 2014 Oct 17;289(42):29322-33
pubmed: 25164813
Mol Neurodegener. 2007 Sep 06;2:17
pubmed: 17822548
Biochem J. 1990 Jul 1;269(1):61-4
pubmed: 2115775
J Neurosci. 2013 Jan 16;33(3):1024-37
pubmed: 23325240

Auteurs

C Laura Sayas (CL)

Centre for Biomedical Research of the Canary Islands (CIBICAN), Institute for Biomedical Technologies (ITB), University of La Laguna (ULL), Tenerife, Spain.

Miguel Medina (M)

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain, CIEN Foundation, Queen Sofia Foundation Alzheimer Center, Madrid, Spain.

Raquel Cuadros (R)

Centro de Biología Molecular Severo Ochoa (CBMSO) CSIC-UAM, Madrid, Spain.

Ivanna Ollá (I)

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain, CIEN Foundation, Queen Sofia Foundation Alzheimer Center, Madrid, Spain.

Esther García (E)

Centro de Biología Molecular Severo Ochoa (CBMSO) CSIC-UAM, Madrid, Spain.

Mar Pérez (M)

Departamento de Anatomía Histología y Neurociencia, Facultad de Medicina UAM, Madrid, Spain.

Isidro Ferrer (I)

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain, CIEN Foundation, Queen Sofia Foundation Alzheimer Center, Madrid, Spain.
Department of Pathology and Experimental Therapeutics, University of Barcelona, Barcelona, Spain.
Service of Pathologic Anatomy, Bellvitge University Hospital, Barcelona, Spain.
Institute of Neurosciences, University of Barcelona, Hospitalet de Llobregat, Spain.

Félix Hernández (F)

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain, CIEN Foundation, Queen Sofia Foundation Alzheimer Center, Madrid, Spain.
Centro de Biología Molecular Severo Ochoa (CBMSO) CSIC-UAM, Madrid, Spain.

Jesús Avila (J)

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain, CIEN Foundation, Queen Sofia Foundation Alzheimer Center, Madrid, Spain.
Centro de Biología Molecular Severo Ochoa (CBMSO) CSIC-UAM, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH